stockportfolio.pro
Stocks / DXCM vs ONC
DXCM vs ONC
DexCom, Inc. and BeOne Medicines AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| DexCom, Inc. (DXCM) | BeOne Medicines AG (ONC) | |
|---|---|---|
| Market cap | $28.6B | $27.0B |
| Revenue (latest FY) | $4.66B | $5.34B |
| Net income (latest FY) | $836.30M | $286.93M |
| Revenue growth (5y CAGR) | 19.3% | 76.8% |
| Net margin | 17.9% | 5.4% |
| Return on equity | 30.5% | 6.6% |
| P/E ratio | 32.4 | 58.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 1 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DXCM — free Open ONC — freeFrequently asked questions
Which is bigger, DXCM or ONC?
DexCom, Inc. is larger by market capitalization — $28.6B versus $27.0B.
Which grows faster, DXCM or ONC?
Over the last five fiscal years, BeOne Medicines AG grew revenue faster — 76.8%/yr versus 19.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.